APA (7th ed.) Citation

H, B., X, A., B, C., M, B., E, A., P, N., . . . J, E. (2025). A multicentric national phase II trial assessing TIslelizumab in monotherapy for patients with Hepatocellular Carcinoma Child-Pugh B and ALBI grade 1 or 2 liver function score: The UCGI 41 HESTIA TRIAL DESIGN AND PRELIMINARY SAFETY Data. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 57(10), 2011. https://doi.org/10.1016/j.dld.2025.07.019

Chicago Style (17th ed.) Citation

H, Bourien, et al. "A Multicentric National Phase II Trial Assessing TIslelizumab in Monotherapy for Patients with Hepatocellular Carcinoma Child-Pugh B and ALBI Grade 1 or 2 Liver Function Score: The UCGI 41 HESTIA TRIAL DESIGN AND PRELIMINARY SAFETY Data." Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 57, no. 10 (2025): 2011. https://doi.org/10.1016/j.dld.2025.07.019.

MLA (9th ed.) Citation

H, Bourien, et al. "A Multicentric National Phase II Trial Assessing TIslelizumab in Monotherapy for Patients with Hepatocellular Carcinoma Child-Pugh B and ALBI Grade 1 or 2 Liver Function Score: The UCGI 41 HESTIA TRIAL DESIGN AND PRELIMINARY SAFETY Data." Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, vol. 57, no. 10, 2025, p. 2011, https://doi.org/10.1016/j.dld.2025.07.019.